title: Clinical significance of development of Philadelphia-chromosome negative clones in patients with chronic myeloid leukemia treated with imatinib mesylate.
authors.affiliation: Queensland Health Pathology Service, Royal Brisbane and Women's Hospital, Herston, Queensland, Australia.
authors.forename: J M
authors.initials: JM
authors.lastname: Perel
authors.forename: C
authors.initials: C
authors.lastname: McCarthy
authors.forename: O
authors.initials: O
authors.lastname: Walker
authors.forename: I
authors.initials: I
authors.lastname: Irving
authors.forename: B
authors.initials: B
authors.lastname: Williams
authors.forename: G A
authors.initials: GA
authors.lastname: Kennedy
mesh_terms: D000208:Acute Disease; D000368:Aged; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use; D001549:Benzamides; D001853:Bone Marrow / Q000473:pathology; D002999:Clone Cells / Q000648:ultrastructure*; D003561:Cytarabine / Q000008:administration & dosage; D018450:Disease Progression; D017809:Fatal Outcome; D016044:Fusion Proteins, bcr-abl / Q000037:antagonists & inhibitors / Q000235:genetics; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage; D006801:Humans; D006918:Hydroxyurea / Q000008:administration & dosage; D000068877:Imatinib Mesylate; D017404:In Situ Hybridization, Fluorescence; D007372:Interferons / Q000008:administration & dosage; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics / Q000473:pathology; D007951:Leukemia, Myeloid / Q000235:genetics* / Q000473:pathology; D015466:Leukemia, Myeloid, Chronic-Phase / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics / Q000473:pathology; D008297:Male; D008875:Middle Aged; D014411:Neoplastic Stem Cells / Q000187:drug effects* / Q000201:enzymology; D010677:Philadelphia Chromosome; D010879:Piperazines / Q000494:pharmacology / Q000627:therapeutic use*; D047428:Protein Kinase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D011743:Pyrimidines / Q000494:pharmacology / Q000627:therapeutic use*; D012641:Selection, Genetic; D014740:Vidarabine / Q000008:administration & dosage / Q000031:analogs & derivatives
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D047428:Protein Kinase Inhibitors; D011743:Pyrimidines; D003561:Cytarabine; D016179:Granulocyte Colony-Stimulating Factor; D000068877:Imatinib Mesylate; D007372:Interferons; D016044:Fusion Proteins, bcr-abl; D014740:Vidarabine; D006918:Hydroxyurea